Chapter 17: Immune Modulators

Immune Modulators pharmacology chapter explores the category of Immune Modulators, drugs utilized to strategically adjust the body’s protective mechanisms for therapeutic purposes, dividing them broadly into Immune Stimulants and Immune Suppressants. Immune Stimulants are designed to energize a weakened immune system or assist in combating specific threats like cancer or prolonged invasions, and they are classified into three major groups. Interferons (such as interferon alfa-2b), which are naturally produced in response to viral invasion, function by preventing viral replication and stimulating cytotoxic T-cell activity, and are used for conditions including various cancers and hepatitis. Interleukins (like aldesleukin) enhance cellular immunity, increase the activity of natural killer cells and lymphocytes, and inhibit tumor growth, targeting specific metastatic cancers. Colony-Stimulating Factors (CSFs) (including filgrastim) boost the production of white blood cells, primarily neutrophils, in the bone marrow to reduce infection risk in patients undergoing chemotherapy or bone marrow transplants. A hallmark adverse effect across the stimulant class is a flu-like syndrome, characterized by fever, lethargy, muscle aches, and anorexia. Conversely, Immune Suppressants are necessary to block the aggressive immune response, primarily to prevent the rejection of transplanted organs or to manage destructive autoimmune disorders where the body attacks itself. This category includes Immune Modulators (such as fingolimod, the first oral agent for relapsing multiple sclerosis) that block the release of inflammatory cytokines; T- and B-Cell Suppressors (with cyclosporine as a prototype, commonly used for transplant prophylaxis) which inhibit lymphocyte function and antibody production; and Monoclonal Antibodies (Mabs). Mabs are highly specific antibodies designed to react with single, precise antigens or receptor sites. Examples include adalimumab and infliximab which target tumor necrosis factor (TNF) for treating arthritis, trastuzumab targeting the HER2 receptor in specific breast cancers, and palivizumab used to prevent respiratory syncytial virus (RSV) disease in high-risk children. A critical concern with all immune suppressants is the increased, potentially dangerous susceptibility to infection and the higher risk of developing neoplasms. Nursing care mandates extensive teaching regarding proper injection techniques, strict infection avoidance measures, close monitoring of renal and liver function, and mandatory use of barrier contraceptives for women of childbearing age due to the drugs' teratogenic potential.